Latest Conference Coverage

Post-Hoc Analysis of ADAPT Reveals Several Subgroup Responders to Efgartigimod

Efgartigimod-treated patients consistently outperformed placebo regardless of concomitant medication, thymectomy status, and timing of diagnosis.

Post-Hoc Analysis of CHAMPION MG Study Highlights Ravulizumab’s Effects on Specific Muscle Domains

After previously showing positive effects on MG-ADL and QMG, ravulizumab continued to show improvements in ocular and respiratory muscle domains in myasthenia gravis.

Turning Gene Therapy Into Reality: Peter Marks, MD, PhD

The director of the Center for Biologics Evaluation Research at the FDA provided an overview of the Keynote Address he gave at the 2023 Muscular Dystrophy Association Clinical and Scientific Conference. [WATCH TIME: 3 minutes]

Supplementing N-163 Beta Glucan Shows Disease-Modifying Effects as Adjuvant in Duchenne Muscular Dystrophy

More than 90% of patients, ambulatory and non-ambulatory, experienced improvements in Medical Research Council score within 6 months of treatment.

Minor Differences in Inclusion Criteria, Baseline Characteristics Impact Motor and Nonmotor Clinical Outcomes in Presymptomatic Spinal Muscular Atrophy

Differences in baseline characteristics and eligible criteria in presymptomatic infants with spinal muscular atrophy led to differential results on motor and nonmotor clinical outcomes.

Balancing Efficacy and Safety With MS Disease-Modifying Therapies: Omar Al-Louzi, MD

The director of the Visual Outcomes Laboratory at Cedars Sinai talked about the current treatments used in MS and the risks associated with them at 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]

Using MRIs to Detect Early Signs of Viral Infections in Multiple Sclerosis

At the 2023 ACTRIMS forum, Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, talked about investigating the relationship between viral infections and multiple sclerosis using MRIs.

Applying Artificial Intelligence to Monitor Multiple Sclerosis Disease Progression

Michael Dwyer, PhD, director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center, provided insight on how artificial intelligence techniques may be used to monitor disease progression in multiple sclerosis.

Sustainability and Future of Intermittent Calorie Restriction in Multiple Sclerosis: Laura Piccio, MD, PhD

The neurologist and physician scientist at Washington University in St. Louis provided perspective on the need for additional studies assessing the long-term effects of dieting strategies in multiple sclerosis. [WATCH TIME: 3 minutes]

Exploring New Therapies for MS With Research on T-bet+ memory B Cells: Rajiv Jain, PhD

At the 2023 ACTRIMS, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary, spoke on the impact of researching T-Bet+ memory B cells for new therapies in multiple sclerosis. [WATCH TIME: 5 minutes]

Promising Findings on the Role of T-bet+ Memory B Cells in MS: Rajiv Jain, PhD

At the 2023 ACTRIMS Forum, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary talked about the main findings he observed with B cell therapies in patients with MS. [WATCH TIME: 4 minutes]

Retrograde Trans-Synaptic Degeneration in MS and its Impact on Visual Function

Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, provided his clinical perspective on role of imaging and viral infections in patients with MS at the 2023 ACTRIMS forum.

Top Interviews from 2023 ACTRIMS: Expert Insights on Multiple Sclerosis

A group of experts in the care of patients with multiple sclerosis—Marisa McGinley, DO; Farrah Mateen, MD, PhD; Laura Piccio, MD, PhD; Robert Zivadinov, MD, PhD; and Bruce Cree, MD, PhD, MAS, FAAN—shared their perspectives on hot topics of treatment and management from the 2023 ACTRIMS Forum.

Proven Therapies Underutilized in State of Care for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center spoke about the barriers in accessing proven therapies for NMOSD at the 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]

Potential Therapies Targeting Memory B-Cells to Prevent Relapse and Progression in MS

Rajiv Jain, PhD, post-doctoral associate, department of clinical neurosciences, University of Calgary, talked about his presentation on T-bet+ memory B-cells in multiple sclerosis at the 2023 ACTRIMS Forum.

Significance of Evusheld’s Effect in Multiple Sclerosis: Svetlana P. Eckert, MD

The clinical assistant professor of neurology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, talked about her presentation on Evusheld at the 2023 ACTRIMS Forum. [WATCH TIME: 5 minutes]

Utilizing Biomarker Panels to Effectively Gauge, Manage Multiple Sclerosis

Taylor Gonyou, DO, a multiple sclerosis fellow at Michigan Institute for Neurologic Disorders, detailed a proteomic biomarker panel that gauges multiple sclerosis disease activity, with potential to impact clinical decision-making.

Overcoming Issues With Access to MRIs, Resources in Care of Multiple Sclerosis: Robert Zivadinov, MD, PhD

The director of the Buffalo Neuroimaging Analysis Center provide perspective on innovative ways to monitor progression in multiple sclerosis, and the importance of high-level care facilities. [WATCH TIME: 5 minutes]

Role of Evusheld in Preventing COVID Infections in Multiple Sclerosis

Svetlana P. Eckert, MD, clinical assistant professor of neurology at University at Buffalo, talked about Evusheld as a preventive approach to COVID-19 infections in multiple sclerosis at the 2023 ACTRIMS Forum.

Investigating Effectiveness of COVID-19 Vaccination in Patients on B-Cell Depleting Therapies: Bruce Cree, MD, PhD, MAS, FAAN

At the 2023 ACTRIMS Forum, the clinical research director of the UCSF Multiple Sclerosis Center talked about the implications for patients on B-cell depleting therapies infected with COVID-19. [WATCH TIME: 4 minutes]

Vaccine Status and Hypogammaglobulinemia in N-MOmentum Trial Analyses: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center spoke on the findings from two post-hoc analyses that were presented at the 2023 ACTRIMS Conference. [WATCH TIME: 3 minutes]

Assessing Deep Gray Matter Loss in Cortical, Thalamic Regions to Understand MS Progression: Robert Zivadinov, MD, PhD

The director of the Buffalo Neuroimaging Analysis Center discussed the need to further explain differences in cortical lesions and deep gray matter in patients with severely affected multiple sclerosis. [WATCH TIME: 4 minutes]

Challenges With Tailoring Diets in Multiple Sclerosis: Laura Piccio, MD, PhD

The neurologist and physician scientist at Washington University in St. Louis provided insight on the general dieting strategies patients with multiple sclerosis should take as more information becomes available. [WATCH TIME: 6 minutes

Ganaxolone’s Significant Effect on CDKL5 Deficiency Disorder: Elia Pestana-Knight, MD

The pediatric epileptologist at Cleveland Clinic provided insight on her presentation at the 2022 AAN Annual Meeting that evaluated ganaxolone in phase 3 study of patients with CDKL5 deficiency disorder. [WATCH TIME: 4 minutes]

Recapping Research From 2023 ACTRIMS

As a recap from ACTRIMS 2023, get caught up on some of the latest news in multiple sclerosis as the NeurologyLive® team shares some of our data updates.

Identifying Reasons, Barriers to Low Employment Rates in NMOSD: Farrah Mateen, MD, PhD

The associate director of the Multiple Sclerosis & Neuromyelitis Optica Unit at Massachusetts General Hospital provided perspective on a study that linked NMOSD to increased unemployment and decreased income. [WATCH TIME: 6 minutes]

Positive Response of Telehealth as Additional Option for Care in MS: Marisa McGinley, DO

The staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic discussed how patients with multiple sclerosis are more open to using telehealth for accessing their healthcare providers at the 2023 ACTRIMS Forum. [WATCH TIME: 4 minutes]

Differentiating Severe Multiple Sclerosis Through a Comprehensive Assessment: Robert Zivadinov, MD, PhD

The director of the Buffalo Neuroimaging Analysis Center provided context on the CASA-MS study, and the key differences in why certain patients with multiple sclerosis experience more rapid disability progression. [WATCH TIME: 4 minutes]

Metabolic Changes, Cognitive Improvements in Multiple Sclerosis Observed Through Intermittent Calorie Restriction

Compared with those on an unrestricted diet, patients with MS on intermittent calorie restriction showed greater cognitive performance, as assessed by SDMT, after 12 weeks dieting.

Building Trust and Increasing Patient Engagement With MS Communities: Marisa McGinley, DO

At the 2023 ACTRIMS Forum, the staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic talked about the lack of trust and engaging more with the MS community. [WATCH TIME: 5 minutes]